ScreenerHero

CLNN Clene Inc.

NAS · US · Consumer Defensive · Packaged Foods · clene.com
3.920USD+1.29%Mkt Cap: 55.72M $P/E: —

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, w…

Industry Peers

Packaged Foods
Screen all
BN
Danone S.A.
$41.15BUSDP/E 19.5
JBS
JBS N.V.
$40.26BUSDP/E 11.4
KHC
The Kraft Heinz Company
$28.90BUSD
KHC
The Kraft Heinz Company
$26.06BUSD
GIS
General Mills, Inc.
$16.99BUSD
KRZ
Kerry Group plc
$15.10BUSDP/E 22.6
KYGA
Kerry Group plc
$14.89BUSDP/E 21.8
ABF
Associated British Foods plc
$13.87BUSDP/E 13.7
MKC-V
McCormick & Company, Incorporated
$13.58BUSDP/E 8.4
SJM
The J. M. Smucker Company
$12.38BUSDP/E 54.2
MKC
McCormick & Company, Incorporated
$12.18BUSDP/E 7.5
LOTB
Lotus Bakeries NV
$10.99BUSDP/E 53.0
HRL
Hormel Foods Corporation
$10.76BUSDP/E 31.5
SAP
Saputo Inc.
$11.13BUSDP/E 22.4
MICC
The Magnum Ice Cream Company N.V.
$9.98BUSDP/E 36.2
MICC
The Magnum Ice Cream Company N.V.
$10.24BUSDP/E 34.6
DAR
Darling Ingredients Inc.
$9.47BUSDP/E 16.2
ORK
Orkla ASA
$8.23BUSDP/E 14.0
SFD
Smithfield Foods, Inc.
$7.28BUSDP/E 6.9
PPC
Pilgrim's Pride Corporation
$6.70BUSDP/E 12.3
HeadlineSourceTime
Older
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene (NASDAQ:CLNN) is preparing to submit a New Drug Application, or NDA, seeking accelerated approval for CNM-Au8 in amyotrophic lateral sclerosis, or ALS, after completing additional analyses requested by the U.S. Food and Drug Administration, President and CEO Rob Etherington said in an intervie

MarketBeat
Clene Inc. (CLNN) Reports Q2 Loss, Beats Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -62.16% and +38.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Clene Targets Early Q4 NDA Filing for CNM-Au8 in ALS

Clene (NASDAQ:CLNN) said it is preparing to submit a new drug application, or NDA, in early fourth quarter for CNM-Au8 as a potential treatment for amyotrophic lateral sclerosis, following a series of meetings with the U.S. Food and Drug Administration. President and CEO Rob Etherington said the co

MarketBeat
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue Estimates

Microbot Medical (MBOT) delivered earnings and revenue surprises of 0.00% and -22.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks